BridgeBio Pharma, Inc. (BBIO)

BridgeBio Pharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	353.78	221.9	9.3	77.65	69.72	8.25
Revenue Growth (YoY)	62.46%	2285.27%	-88.02%	11.38%	745.14%	-79.66%
Cost of Revenue	14.94	3.88	2.45	3.43	3.11	-
Gross Profit	338.84	218.02	6.86	74.21	66.6	8.25
Selling, General & Admin	451.42	272.43	150.59	143.19	188.91	145.68
Research & Development	465.89	506.46	455.71	399.46	451.02	337.05
Operating Expenses	917.31	778.89	606.3	542.65	639.93	482.73
Operating Income	-578.47	-560.87	-599.44	-468.44	-573.33	-474.48
Interest Expense	-157.75	-99.29	-81.29	-80.44	-46.78	-36.66
Interest & Investment Income	20.21	17.25	18.04	7.54	1.13	4.01
Earnings From Equity Investments	-68.27	-31.18	-	-	-	-
Other Non Operating Income (Expenses)	32.86	4.14	0.3	102.43	3.7	1.63
EBT Excluding Unusual Items	-751.42	-669.96	-662.4	-438.9	-615.28	-505.49
Merger & Restructuring Charges	-15.18	-15.61	-7.93	-43.77	-	-
Gain (Loss) on Sale of Investments	-	8.14	18.31	-8.22	29.91	-
Gain (Loss) on Sale of Assets	-	178.32	-1.24	-6.26	-	-
Asset Writedown	0.27	-	-	-	-3.3	-
Other Unusual Items	-37.66	-43.09	-	12.5	2.21	-
Pretax Income	-803.98	-542.19	-653.25	-484.65	-586.45	-505.49
Income Tax Expense	1.71	1.15	-	-	-	-
Earnings From Continuing Operations	-805.69	-543.35	-653.25	-484.65	-586.45	-505.49
Minority Interest in Earnings	8.57	7.59	10.05	3.47	23.92	56.76
Net Income	-797.12	-535.76	-643.2	-481.18	-562.54	-448.72
Net Income to Common	-797.12	-535.76	-643.2	-481.18	-562.54	-448.72
Shares Outstanding (Basic)	190	186	163	147	144	118
Shares Outstanding (Diluted)	190	186	163	147	144	118
Shares Change (YoY)	4.48%	14.30%	10.39%	2.16%	22.34%	12.27%
EPS (Basic)	-4.18	-2.88	-3.95	-3.26	-3.90	-3.80
EPS (Diluted)	-4.18	-2.88	-3.95	-3.26	-3.90	-3.80
Free Cash Flow	-585.93	-521.66	-529.03	-424.32	-511.18	-407.23
Free Cash Flow Per Share	-3.08	-2.80	-3.25	-2.88	-3.54	-3.45
Gross Margin	95.78%	98.25%	73.71%	95.58%	95.53%	100.00%
Operating Margin	-163.51%	-252.76%	-6443.56%	-603.28%	-822.38%	-5751.99%
Profit Margin	-225.32%	-241.44%	-6913.92%	-619.70%	-806.90%	-5439.74%
Free Cash Flow Margin	-165.62%	-235.08%	-5686.62%	-546.46%	-733.23%	-4936.74%
EBITDA	-573.1	-554.79	-592.95	-461.67	-567.49	-473.03
EBITDA Margin	-161.99%	-250.02%	-	-	-	-
D&A For EBITDA	5.37	6.08	6.49	6.77	5.84	1.46
EBIT	-578.47	-560.87	-599.44	-468.44	-573.33	-474.48
EBIT Margin	-163.51%	-252.76%	-	-	-	-
Revenue as Reported	131.88	-	-	-	-	8.25
Advertising Expenses	-	21.5	-	-	-	-

Updated Oct 29, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q